A combination of three biomarkers accurately predicted abnormal accumulation of beta-amyloid plaques in the brains of living Alzheimer's disease patients.
The researchers developed a plasma protein signature that can identify patients with cerebrospinal fluid amyloid-β42 levels indicative of risk for the disease.
The study is part of a broader effort by academic and industry researchers to develop blood-based tests for easier, less expensive Alzheimer's screening.
According to researchers, measurement of serum neurofilament light chain levels could aid in early diagnosis and monitoring of the progression of disease.
The assay uses the propensity of pathogenic tau protein filaments to self-assemble and could enable more accurate and earlier detection of Alzheimer's.
The firm is seeking damages and various injunctions, citing 11 different counts of fraud, breach of contract, tortious interference, and unfair competition.
IQuity develops tests that use RNA expression data to predict, detect, and monitor disease, as well as stratify patients by severity of disease.
The companies will work together to develop new biomarkers and diagnostic methods for Alzheimer's disease, including ones based on amyloid beta protofibrils.
Revenues for Roche Diagnostics totaled CHF 6.26 billion for H1, driven primarily by demand for immunodiagnostic solutions.
The Elecsys beta-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF assays are used to measure peptide biomarkers in the CSF of patients with cognitive impairment.